Background: Vasopressin is an alternative drug to adrenaline in intractable ventricular fibrillation. However, vasopressin can cause significant bradycardia, resulting in reduced cardiac output. We investigated whether pre-treatment with atropine abrogates vasopressin-induced bradycardia in a beating-heart canine model.
Material/methods: Five adult mongrel dogs received endotracheal vasopressin (1.0 U/kg) with or without endotracheal atropine (0.02 mg/kg) or a placebo (10 ml saline) after being anesthetized and ventilated. Hemodynamic variables and arterial blood gases were determined. Each dog (studied 3 times, one week apart) served as its own control.
Results: Endotracheal vasopressin produced early and significant (p<0.05) bradycardia (from 55+/-7 mmHg to 35+/-5 beats/min) compared with controls, starting one minute post-injection and lasting one hour. In contrast, in atropine-pretreated animals the heart rate increased significantly (p<0.05) for as long as one hour post-atropine and vasopressin administration. In addition, animals treated with vasopressin with or without atropine exhibited a significant rise in diastolic blood pressure (from 83+/-5 to 160+/-15 and from 83+/-3 to 108+/-10 mmHg, respectively). Systolic and mean blood pressures also increased significantly compared with controls. Blood gases remained unchanged in all groups.
Conclusions: Endotracheal administration of vasopressin can cause protracted bradycardia. Pretreatment with atropine can abrogate this effect. We suggest that atropine administration be considered when vasopressin is administered during cardio-pulmonary resuscitation. Further studies are warranted to evaluate the effect of vasopressin and atropine in a closed-chest model of cardio-pulmonary resuscitation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Vasopressor or advanced airway first in cardiac arrest?
Resuscitation
December 2024
University of Washington, USA. Electronic address:
Article Synopsis
- The research investigated the impact of the order in which vasopressors and advanced airway management are administered during out-of-hospital cardiac arrest (OHCA) on patient outcomes, specifically looking at data from the Pragmatic Airway Resuscitation Trial (PART).
- Out of 3,004 patients from the trial, the analysis focused on 2,404 individuals, finding no significant difference in survival rates or return of spontaneous circulation based on whether vasopressors or advanced airway interventions were performed first.
- The study concluded that the sequence of administering vasopressors and airway management did not affect patient outcomes or the quality of CPR delivered during resuscitation efforts.
Pharmacokinetic and pharmacodynamic evaluation of various vasopressin doses and routes of administration in a neonatal piglet model.
Sci Rep
October 2024
Centre for the Studies of Asphyxia and Resuscitation, Neonatal Research Unit, Royal Alexandra Hospital, 10240 Kingsway Avenue NW, Edmonton, AB, T5H 3V9, Canada.
Article Synopsis
- Epinephrine is the only vasopressor recommended for neonatal cardiopulmonary resuscitation, but it may have adverse effects that reduce its effectiveness.
- Researchers tested vasopressin as an alternative, comparing its effects when administered through different routes (IV, IO, ETT, IN) in neonatal piglets.
- The study found that IO administration significantly improved hemodynamic parameters, while ETT and IN routes showed lower absorption and were not effective; IV and IO routes were deemed most effective for vasopressin delivery.
Management Strategies for Acute Pulmonary Embolism in the ICU.
Chest
December 2024
Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California, San Diego, La Jolla, CA.
Topic Importance: Acute pulmonary embolism (PE) is a common disease encountered by pulmonologists, cardiologists, and critical care physicians throughout the world. For patients with high-risk acute PE (defined by systemic hypotension) and intermediate high-risk acute PE (defined by the absence of systemic hypotension, but the presence of numerous other concerning clinical and imaging features), intensive care often is necessary. Initial management strategies should focus on optimization of right ventricle (RV) function while decisions about advanced interventions are being considered.
View Article and Find Full Text PDFCardiac Agents during Neonatal Cardiopulmonary Resuscitation.
Neonatology
April 2024
Centre for the Studies of Asphyxia and Resuscitation, Neonatal Research Unit, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Background: Epinephrine (adrenaline) is currently the only cardiac agent recommended during neonatal resuscitation. The inability to predict which newborns are at risk of requiring resuscitative efforts at birth has prevented the collection of large, high-quality human data.
Summary: Information on the optimal dosage and route of epinephrine administration is extrapolated from neonatal animal studies and human adult and pediatric studies.
Encephalopathy in a Recent Lung Transplant Recipient.
Chest
March 2022
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
A 27-year-old man with a history of bronchiolitis obliterans caused by a severe viral illness during early childhood that necessitated lung transplantation who was receiving tacrolimus therapy presented with rapidly worsening mental status. Prior to his change in mental status, his postoperative course was complicated by severe primary graft dysfunction and acute renal failure due to acute tubular necrosis that required continuous renal replacement therapy (CRRT). The patient had a prolonged intubation that required periodic BAL for mucous plugging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!